NCT04722627View on ClinicalTrials.gov

Study of AT-752 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

November 14, 2021

Study Completion Date

November 14, 2021

Conditions
Dengue
Interventions
DRUG

AT-752

Parallel Assignment

DRUG

Placebo

Parallel Assignment

Trial Locations (1)

3004

Atea Study Site, Melbourne

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT04722627 - Study of AT-752 in Healthy Subjects | Biotech Hunter | Biotech Hunter